title: Clinical and microbiological evaluation of pefloxacin in lower respiratory tract infections.
abstract: Patients with Gram-negative lower respiratory tract infections (acute exacerbation of chronic bronchitis (n = 23), pneumonia (n = 4), and bronchiectasis (n = 5) were treated with pefloxacin, 400 mg twice daily, given either intravenously or orally. Symptoms, signs and sputum volume and colour were monitored daily. Chest X-rays, sputum culture and Gram-stain examinations were carried out on days 1 and 5, and immediately after the end of the treatment. There was a clinical improvement, as indicated by the incidence of cough, dyspnoea and rales, and by sputum volume and colour in 31 patients (97%). Microbiological improvement, as indicated by the complete elimination of sputum pathogens and pus cells, was achieved in 28 of the patients (88%). In one patient, an adverse effect, renal failure, occurred. These results suggest that pefloxacin is both clinically and microbiologically effective for the treatment of Gram-negative lower respiratory tract infections.
authors.affiliation: Pulmonary Department, Evangelismos Hospital, Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Tatsis
authors.forename: G
authors.initials: G
authors.lastname: Tsoukalas
authors.forename: V
authors.initials: V
authors.lastname: Hatzinikolaou
authors.forename: G
authors.initials: G
authors.lastname: Boulbasakos
authors.forename: J
authors.initials: J
authors.lastname: Jordanoglou
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy / Q000382:microbiology; D058186:Acute Kidney Injury / Q000139:chemically induced; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001987:Bronchiectasis / Q000188:drug therapy / Q000382:microbiology; D001991:Bronchitis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D015366:Pefloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D016868:Serratia Infections / Q000188:drug therapy / Q000382:microbiology; D013183:Sputum / Q000382:microbiology
chemical_list: D000890:Anti-Infective Agents; D015366:Pefloxacin